Gyrate atrophy of the choroid and retina - Approaches to therapy

Richard Weleber, Nancy G. Kennaway, Neil R M Buist

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Gyrate atrophy of the choroid and retina is caused by deficient activity of ornithine ketoacid aminotransferase, a pyridoxal phosphate dependent enzyme. Besides the typical eye findings, abnormalities have been found on muscle biopsy, electro-encephalography, electromyography and electrocardiography, establishing this as a generalized disorder. Ornithine is markedly elevated in plasma and other body fluids. Plasma lysine, glutamate, glutamine and creatine are reduced. The possible contributions of these biochemical disturbances to the pathogenesis of gyrate atrophy are discussed. The disease is one of the few examples of an inherited chorioretinal dystrophy whose underlying biochemical defect is known. It therefore offers a unique opportunity to develop and test rational approaches to therapy. These include lowering of the abnormally high ornithine by dietary restriction of its precursor arginine, facilitation of ornithine excretion by administation of α-aminoisobutyric acid, replacement of deficient products such as lysine or creatine, or increasing residual enzyme activity by high levels of cofactor (vitamin B6). The results of several studies employing such approaches to therapy are presented as well as preliminary indications of possible benefit in a few patients.

Original languageEnglish (US)
Pages (from-to)23-32
Number of pages10
JournalInternational Ophthalmology
Volume4
Issue number1-2
DOIs
StatePublished - Aug 1981

Fingerprint

Gyrate Atrophy
Ornithine
Creatine
Lysine
Ornithine-Oxo-Acid Transaminase
Eye Abnormalities
Aminoisobutyric Acids
Vitamin B 6
Pyridoxal Phosphate
Body Fluids
Electromyography
Enzymes
Glutamine
Arginine
Glutamic Acid
Electrocardiography
Therapeutics
Biopsy
Muscles

Keywords

  • creatine
  • gyrate atrophy
  • lysine
  • ornithine
  • vitamin B

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Gyrate atrophy of the choroid and retina - Approaches to therapy. / Weleber, Richard; Kennaway, Nancy G.; Buist, Neil R M.

In: International Ophthalmology, Vol. 4, No. 1-2, 08.1981, p. 23-32.

Research output: Contribution to journalArticle

Weleber, Richard ; Kennaway, Nancy G. ; Buist, Neil R M. / Gyrate atrophy of the choroid and retina - Approaches to therapy. In: International Ophthalmology. 1981 ; Vol. 4, No. 1-2. pp. 23-32.
@article{c8e89be8d8fe49dbb899337f814c020e,
title = "Gyrate atrophy of the choroid and retina - Approaches to therapy",
abstract = "Gyrate atrophy of the choroid and retina is caused by deficient activity of ornithine ketoacid aminotransferase, a pyridoxal phosphate dependent enzyme. Besides the typical eye findings, abnormalities have been found on muscle biopsy, electro-encephalography, electromyography and electrocardiography, establishing this as a generalized disorder. Ornithine is markedly elevated in plasma and other body fluids. Plasma lysine, glutamate, glutamine and creatine are reduced. The possible contributions of these biochemical disturbances to the pathogenesis of gyrate atrophy are discussed. The disease is one of the few examples of an inherited chorioretinal dystrophy whose underlying biochemical defect is known. It therefore offers a unique opportunity to develop and test rational approaches to therapy. These include lowering of the abnormally high ornithine by dietary restriction of its precursor arginine, facilitation of ornithine excretion by administation of α-aminoisobutyric acid, replacement of deficient products such as lysine or creatine, or increasing residual enzyme activity by high levels of cofactor (vitamin B6). The results of several studies employing such approaches to therapy are presented as well as preliminary indications of possible benefit in a few patients.",
keywords = "creatine, gyrate atrophy, lysine, ornithine, vitamin B",
author = "Richard Weleber and Kennaway, {Nancy G.} and Buist, {Neil R M}",
year = "1981",
month = "8",
doi = "10.1007/BF00139577",
language = "English (US)",
volume = "4",
pages = "23--32",
journal = "International Ophthalmology",
issn = "0165-5701",
publisher = "Springer Netherlands",
number = "1-2",

}

TY - JOUR

T1 - Gyrate atrophy of the choroid and retina - Approaches to therapy

AU - Weleber, Richard

AU - Kennaway, Nancy G.

AU - Buist, Neil R M

PY - 1981/8

Y1 - 1981/8

N2 - Gyrate atrophy of the choroid and retina is caused by deficient activity of ornithine ketoacid aminotransferase, a pyridoxal phosphate dependent enzyme. Besides the typical eye findings, abnormalities have been found on muscle biopsy, electro-encephalography, electromyography and electrocardiography, establishing this as a generalized disorder. Ornithine is markedly elevated in plasma and other body fluids. Plasma lysine, glutamate, glutamine and creatine are reduced. The possible contributions of these biochemical disturbances to the pathogenesis of gyrate atrophy are discussed. The disease is one of the few examples of an inherited chorioretinal dystrophy whose underlying biochemical defect is known. It therefore offers a unique opportunity to develop and test rational approaches to therapy. These include lowering of the abnormally high ornithine by dietary restriction of its precursor arginine, facilitation of ornithine excretion by administation of α-aminoisobutyric acid, replacement of deficient products such as lysine or creatine, or increasing residual enzyme activity by high levels of cofactor (vitamin B6). The results of several studies employing such approaches to therapy are presented as well as preliminary indications of possible benefit in a few patients.

AB - Gyrate atrophy of the choroid and retina is caused by deficient activity of ornithine ketoacid aminotransferase, a pyridoxal phosphate dependent enzyme. Besides the typical eye findings, abnormalities have been found on muscle biopsy, electro-encephalography, electromyography and electrocardiography, establishing this as a generalized disorder. Ornithine is markedly elevated in plasma and other body fluids. Plasma lysine, glutamate, glutamine and creatine are reduced. The possible contributions of these biochemical disturbances to the pathogenesis of gyrate atrophy are discussed. The disease is one of the few examples of an inherited chorioretinal dystrophy whose underlying biochemical defect is known. It therefore offers a unique opportunity to develop and test rational approaches to therapy. These include lowering of the abnormally high ornithine by dietary restriction of its precursor arginine, facilitation of ornithine excretion by administation of α-aminoisobutyric acid, replacement of deficient products such as lysine or creatine, or increasing residual enzyme activity by high levels of cofactor (vitamin B6). The results of several studies employing such approaches to therapy are presented as well as preliminary indications of possible benefit in a few patients.

KW - creatine

KW - gyrate atrophy

KW - lysine

KW - ornithine

KW - vitamin B

UR - http://www.scopus.com/inward/record.url?scp=0019793307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019793307&partnerID=8YFLogxK

U2 - 10.1007/BF00139577

DO - 10.1007/BF00139577

M3 - Article

VL - 4

SP - 23

EP - 32

JO - International Ophthalmology

JF - International Ophthalmology

SN - 0165-5701

IS - 1-2

ER -